Alk-Abelló’s GRAZAX Approved in Sweden

ALK-Abelló A/S's tablet-based immunotherapy, GRAZAX, has been approved by the Swedish Medical Products Agency for the treatment of grass pollen allergy. ALK-Abelló will now submit further applications in other European countries via the Mutual Recognition Procedure. ALK-Abelló still expects GRAZAX to be launched in the first European markets by the end of 2006.

According to the approval, treatment with GRAZAX is recommended to be initiated at least eight weeks prior to the grass pollen season. When initiating treatment, it is recommended that the first tablet be taken under the doctor's supervision. As expected, patients suffering from severe asthma, systemic immune diseases and hypersensitivity towards tablet additives should not be treated with GRAZAX.

GRAZAX combines the well-established and documented advantages of immunotherapy with a convenient fast-dissolving tablet formulation. The tablet contains standardised grass allergen extract in daily doses of 75,000 SQ-T. It is placed under the tongue once a day, where it melts in a few seconds. GRAZAX is a baseline treatment that does not require up dosing and induces a protective immune response, which reduces and potentially halts the allergic reaction to grass pollen.

For further information please contact:

Jens Bager,

President and CEO

Tel: +45 45 74 74 45

Email: mailbox@dk.alk-abello.com

Or visit: www.alk-abello.com